Targeted knockdown of SEPT9-v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway

Molecular Cancer Research

Volumn 8, Issue 5, 2010, Pages 643-652

  Amir, Sharon ^a   Golan, Maya ^a   Mabjeesh, Nicola J ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; PROTEASOME; PROTEIN SEPT9 V1; SEPTIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; CYTOSKELETON PROTEIN; GROWTH INHIBITOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SEPT9 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; GENE TARGETING; GENETIC CONSERVATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; TUMOR GROWTH; UBIQUITINATION; CELL MOTION; CELL SHAPE; DEFICIENCY; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULARIZATION;

CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SHAPE; CYTOSKELETAL PROTEINS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GROWTH INHIBITORS; GTP-BINDING PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SEPTINS;

MAMMALIA;

EID: 77952907255     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0497     Document Type: Article

References (34)

1. Semenza GL. Hypoxia and cancer. Cancer Metastasis Rev 2007;26:223-224
2. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-447
3. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-276
4. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda) 2009;24:97-106.
5. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 2007;26:341-352
6. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 2006;4:601-605
7. Rapisarda A, Hollingshead M, Uranchimeg B, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009;8:1867-1877
8. Amir S, Wang R, Matzkin H, Simons JW, Mabjeesh NJ. MSF-A interacts with hypoxia-inducible factor-1α and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis. Cancer Res 2006;66:856-866
9. Barral Y, Kinoshita M. Structural insights shed light onto septin assemblies and function. Curr Opin Cell Biol 2008;20:12-18
10. Weirich CS, Erzberger JP, Barral Y. The septin family of GTPases: architecture and dynamics. Nat Rev Mol Cell Biol 2008;9:478-489
11. Russell SE, Hall PA. Do septins have a role in cancer? Br J Cancer 2005;93:499-503.
12. Garcia W, de Araujo AP, Neto Mde O, et al. Dissection of a human septin: definition and characterization of distinct domains within human SEPT4. Biochemistry 2006;45:13918-13931
13. Amir S, Wang R, Simons JW, Mabjeesh NJ. SEPT9-v1 up-regulates hypoxia-inducible factor 1 by preventing its RACK1-mediated degradation. J Biol Chem 2009;284:11142-11151
14. Gonzalez ME, Peterson EA, Privette LM, Loffreda-Wren JL, Kalikin LM, Petty EM. High SEPT9-v1 expression in human breast cancer cells is associated with oncogenic phenotypes. Cancer Res 2007;67:8554-8564
15. Demichelis F, Fall K, Perner S, et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-4599
16. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008;100:815-825
17. Dang DT, Chen F, Gardner LB, et al. Hypoxia-inducible factor-1α promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 2006;66:1684-1936
18. Amir S, Mabjeesh NJ. SEPT9-V1 protein expression is associated with human cancer cell resistance to microtubule-disrupting agents. Cancer Biol Ther 2007;6:1926-1931
19. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-375
20. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 2001;8:1801-1807
21. Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-2482
22. Wesley UV, Bove PF, Hristova M, McCarthy S, van der Vliet A. Airway epithelial cell migration and wound repair by ATP-mediated activation of dual oxidase 1. J Biol Chem 2007;282:3213-3220
23. Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-466
24. Scott M, McCluggage WG, Hillan KJ, Hall PA, Russell SE. Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. Int J Cancer 2006;118:1325-1329
25. Surka MC, Tsang CW, Trimble WS. The mammalian septin MSF localizes with microtubules and is required for completion of cytokinesis. Mol Biol Cell 2002;13:3532-3545
26. Gonzalez ME, Makarova O, Peterson EA, Privette LM, Petty EM. Up-regulation of SEPT9-v1 stabilizes c-Jun-N-terminal kinase and contributes to its pro-proliferative activity in mammary epithelial cells. Cell Signal 2009;21:477-487
27. Nagata K, Inagaki M. Cytoskeletal modification of Rho guanine nucleotide exchange factor activity: identification of a Rho guanine nucleotide exchange factor as a binding partner for Sept9b, a mammalian septin. Oncogene 2005;24:65-76.
28. Chacko AD, Hyland PL, McDade SS, Hamilton PW, Russell SH, Hall PA. SEPT9-v4 expression induces morphological change, increased motility and disturbed polarity. J Pathol 2005;206:458-465
29. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL. RACK1 competes with HSP90 for binding to HIF-1α and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1α. Mol Cell 2007;25:207-217
30. Liu YV, Semenza GL. RACK1 vs. HSP90: competition for HIF-1 α degradation vs. stabilization. Cell Cycle 2007;6:656-659
31. Gewirtz AM. On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J Clin Invest 2007;117:3612-3614
32. Grimm D. Small silencing RNAs: state-of-the-art. Adv Drug Deliv Rev 2009;61:672-703.
33. Li L, Lin X, Staver M, et al. Evaluating hypoxia-inducible factor-1α as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005;65:7249-7258
34. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL. Silencing of hypoxia inducible factor-1α by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res 2007;13:2441-2448